These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 2782920

  • 21. [Pharmacokinetics of carboplatin in a patient under hemodialysis].
    Kurata H, Yoshiya N, Ikarashi H, Kaneko T, Kodama S, Tanaka K, Suzuki K, Yoshizawa H, Cho T, Suzuki E.
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):547-50. PubMed ID: 8129398
    [Abstract] [Full Text] [Related]

  • 22. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W, Braess J, Kotschofsky M, Samel S, Becker H, Hiddemann W, Schleyer E.
    Anticancer Res; 2002 Mar; 22(5):3099-102. PubMed ID: 12530050
    [Abstract] [Full Text] [Related]

  • 23. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
    Fujii M, Kiura K, Okabe K, Toki H, Kimura M.
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods].
    Takahashi A, Takagi M, Hishida H, Saji E, Takagi N, Amano H, Ogura Y.
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2944-50. PubMed ID: 3116947
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics of cisplatin and methotrexate after M-VAC chemotherapy for advanced urothelial cancer in hemodialysis patients.
    Matsumoto K.
    Int J Urol; 2008 Oct; 15(10):949-50. PubMed ID: 19138292
    [No Abstract] [Full Text] [Related]

  • 27. [Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].
    Furuya Y, Takihana Y, Araki I, Tanabe N, Takeda M.
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):1017-20. PubMed ID: 12894722
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Hemodynamics at hepatoarterial infusion of 5-FU in a chronic renal failure patient maintained by hemodialysis].
    Maruyama M, Irie T, Yoshida T, Nagahama T, Sugano N, Ebuchi M.
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2241-5. PubMed ID: 10635312
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T, Pujol JL, Douillard JY, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Besson F.
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [Abstract] [Full Text] [Related]

  • 40. [Studies on adequate intervals of cisplatin administration to ameliorate cisplatin-induced nephrotoxicity].
    Sakatoku H, Kawai K, Kamiya H, Sakurai M.
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):239-46. PubMed ID: 3947105
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.